Mirum Pharmaceuticals, Inc. (MIRM) [Rocket]

Overview

Mirum Pharmaceuticals, Inc. (MIRM)

Add to portfolio

1m \| 3m \| 6m \| 1y \| 2y \| 5y \| 10y

Recent News + Filings (All items)

Date Filed	Type	Description
10/13/2023	S-3ASR	Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers:
10/13/2023	8-K	Quarterly results
08/07/2023	10-Q	Quarterly Report for the period ended June 30, 2023
08/03/2023	8-K	Quarterly results
07/17/2023	8-K	Quarterly results
07/05/2023	4	Radovich Peter (COO) has filed a Form 4 on Mirum Pharmaceuticals, Inc.
07/05/2023	4	Longpre Lara (Chief Development Officer) has filed a Form 4 on Mirum Pharmaceuticals, Inc.

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19
Revenues	77.1	19.1	0.0	0.0
Revenue growth	302.7%
Cost of goods sold	0.0	0.0	0.0	0.0
Gross profit	77.1	19.1	0.0	0.0
Gross margin	100.0%	100.0%
Selling, general and administrative	89.1	192.6	104.3
Research and development		131.4	81.6	43.0
General and administrative				11.8
EBIT	-131.2	-173.4	-104.3	-54.7
EBIT margin	-170.3%	-906.1%
Pre-tax income	-142.1	-84.0	-103.3	-52.5
Income taxes	-6.4	0.0	0.0	0.0
Tax rate	4.5%
Net income	-135.7	-84.0	-103.3	-52.6
Net margin	-176.0%	-438.9%

Diluted EPS	($3.99)	($2.77)	($4.09)	($4.58)
Shares outstanding (diluted)	34.0	30.3	25.3	11.5

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.